Invitae Hereditary Colorectal Cancer Panel
Use
The Invitae Hereditary Colorectal Cancer Panel analyzes genes associated with predisposition to colorectal cancer. Broad panel testing allows for efficient evaluation of potential genes for colorectal cancer susceptibility based on a single clinical indication. It aids in confirming clinical diagnosis, predicting disease prognosis and progression, facilitating early detection of symptoms, informing family planning and genetic counseling, and promoting clinical trial enrollment. This test is designed for heritable germline mutations and not for somatic mutations in tumor tissue.
Special Instructions
This test can be customized by selecting or deselecting specific genes to include or exclude. It is not intended for somatic mutation testing; only germline mutations are evaluated.
Limitations
The assay may have reduced sensitivity for insertions and deletions larger than 15bp but smaller than a full exon. Certain structural rearrangements or variants in sequence with complex architecture (e.g., short tandem repeats) may not be detected. The assay does not guarantee coverage of promoter regions, non-coding exons, and non-coding regions unless specified. Rare single-exon copy number events may not be analyzed due to sequence properties or data quality.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant